WIP 81 - Evaluation of Comprehensive Sexually Transmitted Infection Care in Adolescents

Publication Number: WIP 81.7597

Sarah Sharp, Wake Forest School of Medicine of Wake Forest Baptist Medical Center, Winston-Salem, NC, United States; Candice J. McNeil, Wake Forest School of Medicine of Wake Forest Baptist Medical Center, Winston-salem, NC, United States

Background: Chlamydia is the most common notifiable disease in the United States (US) where adolescents and young adults account for the majority of cases. Rates of all sexually transmitted infections (STIs), including chlamydia, are high and disproportionally noted in the Southern US.

In order to provide comprehensive care, clinicians are recommended to test for concurrent STIs including Human Immunodeficiency Virus (HIV), syphilis, and gonorrhea (GC) as well as to repeat testing for chlamydia 3 to 12 months after initial infection. However, we have limited information on the current adherence to these guidelines. Due to the high rates of STIs in adolescents, particularly in the Southern US, evaluation of STI screening is important to determine how many adolescents are receiving comprehensive STI care.

Objective: To determine the number of adolescents at a single large southern tertiary health center who received concurrent and follow-up testing for STIs as part of comprehensive care after a diagnosis of chlamydia.

Design/Methods: This study is a retrospective chart review that will describe rates of comprehensive STI testing among patients seen at an academic medical center (IRB00072930). Study participants will be adolescents aged 13-19 with a diagnosis of sexually transmitted chlamydia over a 5-year period. Data collected include date of diagnosis with chlamydial infection, laboratory testing for HIV, syphilis, and gonorrhea at the time of initial diagnosis, and laboratory testing for chlamydia 3 months to 1 year after initial diagnosis, and demographic information. Outcome measures include descriptive statistics describing the proportion of patients with a diagnosis of chlamydia who received comprehensive STI screening including testing for HIV, syphilis, gonorrhea and repeat testing for chlamydia 3 and 12 months after initial diagnosis. Data collection is completed and analysis of the fully de-identified data set is expected to be completed by January 2025.